Vigil Neuroscience, Inc.
VIGLDelisted Aug 5, 2025- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001827087
Vigil Neuroscience, Inc. was delisted on Aug 5, 2025; its insiders filed their last Form 4 on Aug 7, 2025; 78 institutions reported holding it in 13F filings for Q2 2025, worth $265.8M in total; no superinvestor held it.
- Currency
- USD
- Source
- SEC XBRL data (10-K, 10-Q, 20-F, 40-F)
- Updated
- Oct 8, 2026, 2:31 PM ET
Income statement
Each column is one fiscal year, newest first.
| Line item | FY2024 | FY2023 | FY2022 |
|---|---|---|---|
| Period end | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 |
| Filing | 10-K | 10-K | 10-K |
| Reported | Mar 13, 2025 | Mar 26, 2024 | Mar 21, 2023 |
| Operating expenses | $89.7M | $88.9M | $68.9M |
| Research and development | $62.3M | $60.9M | $47.4M |
| Selling, general and administrative | $27.4M | $27.9M | $21.4M |
| Operating income | -$89.7M | -$88.9M | -$68.9M |
| Income tax | $0 | $0 | $0 |
| Net income | -$84.3M | -$82.6M | -$68.3M |
| EPS, basic | $-2.07 | $-2.13 | $-2.16 |
| EPS, diluted | $-2.07 | $-2.13 | $-2.16 |
| Weighted shares, basic | 40.7M | 38.7M | 31.7M |
| Weighted shares, diluted | 40.7M | 38.7M | 31.7M |
Balance sheet
Each column is one fiscal year, newest first.
| Line item | FY2024 | FY2023 | FY2022 |
|---|---|---|---|
| Period end | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 |
| Filing | 10-K | 10-K | 10-K |
| Reported | Mar 13, 2025 | Mar 26, 2024 | Mar 21, 2023 |
| Cash and equivalents | $39.0M | $52.0M | $186.6M |
| Short-term investments | $58.8M | $65.9M | – |
| Total current assets | $100.6M | $121.9M | $197.8M |
| Property, plant and equipment | $1.32M | $1.75M | $1.18M |
| Total assets | $117.7M | $140.9M | $200.4M |
| Accounts payable | $1.97M | $1.95M | $1.94M |
| Total current liabilities | $34.1M | $11.7M | $11.3M |
| Total liabilities | $46.1M | $24.6M | $11.3M |
| Shareholders' equity | $71.6M | $116.3M | $189.1M |
Cash flow statement
Each column is one fiscal year, newest first. Free cash flow is operating cash flow minus capital expenditures.
| Line item | FY2024 | FY2023 | FY2022 |
|---|---|---|---|
| Period end | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 |
| Filing | 10-K | 10-K | 10-K |
| Reported | Mar 13, 2025 | Mar 26, 2024 | Mar 21, 2023 |
| Operating cash flow | -$51.2M | -$70.4M | -$65.1M |
| Capital expenditures | $5.00K | $674.0K | $921.0K |
| Free cash flow | -$51.2M | -$71.0M | -$66.1M |
| Depreciation and amortization | $453.0K | $399.0K | $78.0K |
| Stock-based compensation | $10.1M | $8.90M | $5.48M |
| Investing cash flow | $8.76M | -$65.1M | -$921.0K |
| Financing cash flow | $29.5M | $888.0K | $161.3M |
| Net change in cash | -$13.0M | -$134.6M | $95.2M |
Shares outstanding
Common shares outstanding as stated on the cover of each 10-K and 10-Q. The date is the cover date, not the period end; a rising count means dilution.
| Cover date | Shares outstanding | Change in a year | Filing |
|---|---|---|---|
| Jul 31, 2025 | 47.7M | +20.3% | SEC |
| Apr 30, 2025 | 46.7M | +24.2% | SEC |
| Feb 28, 2025 | 46.7M | +26.5% | SEC |
| Oct 31, 2024 | 40.9M | +13.9% | SEC |
| Jul 31, 2024 | 39.6M | +10.5% | SEC |
| Apr 30, 2024 | 37.6M | +5.3% | SEC |
| Feb 29, 2024 | 36.9M | +3.5% | SEC |
| Oct 31, 2023 | 35.9M | +0.8% | SEC |
Notes and known gaps
How these numbers are put together, and what they can't tell you.
- Numbers come from the XBRL data in each period's original 10-K, 10-Q, 20-F or 40-F, or its amendment. They are shown as filed: later filings don't restate earlier periods here.
- Reported is the filing date of the first 8-K with Item 2.02 (results of operations) after the period ended, no later than the 10-Q or 10-K and within 120 days. Companies that release results only in the 10-Q, and foreign companies, which use Form 6-K, have none.
Known gaps
- Foreign companies that file Form 20-F or 40-F have annual statements only: their quarterly results are furnished on Form 6-K, which has no XBRL data.
- EPS and share counts are as reported at the time, not adjusted for later stock splits.
- For ADRs, EPS is per ordinary share, not per ADS (one TSMC ADS is five ordinary shares).
- For banks, revenue may be interest income only, depending on how the bank tags its filings; cost of revenue and gross profit are usually blank.
- Companies with several share classes, such as Berkshire Hathaway, may have no EPS and no cover share count.
- Depreciation and amortization is missing for some companies that report it under their own XBRL tags.